|
Wednesday, August 4, 2021, 5:00 PM – 6:30 PM Eastern Time (ET)
Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Hepatocellular Carcinoma and Pancreatic CancerA Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual MeetingJoin us on Wednesday, August 4th for this CME/MOC-accredited webinar Faculty
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science Program Leader, Gastrointestinal Cancer Mayo Clinic Cancer Center Consultant, Mayo Clinic in Arizona Phoenix, Arizona Kim A Reiss Binder, MD Assistant Professor Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Eileen M O’Reilly, MD Winthrop Rockefeller Endowed Chair in Medical Oncology Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers Co-Director, Medical Initiatives David M Rubenstein Center for Pancreatic Cancer Research Attending Physician, Member Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Cornell Medical College New York, New York
Philip A Philip, MD, PhD, FRCP
Kathryn Cramer Endowed Chair in Cancer Research Professor of Oncology and Pharmacology Leader, GI and Neuroendocrine Oncology Karmanos Cancer Institute Wayne State University Detroit, Michigan Moderator Neil Love, MD Research To Practice Miami, Florida Hepatocellular Carcinoma (HCC)
Pancreatic Cancer
Target Audience Learning Objectives
CME Credit Form Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Disclosure Policy FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process: Dr Bekaii-Saab — Advisory Committee: Immuneering Corporation, Imugene, Sun Biopharma; Consulting Agreements (to Institution): Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences Inc, Foundation Medicine, Janssen Biotech Inc, Kanaph Therapeutics, Natera Inc, Sobi, Treos Bio, Xilis; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Exelixis Inc, Merck, Pancreatic Cancer Action Network; Inventions/Patents: WO/2018/183488, WO/2019/055687. Dr Binder — Contracted Research: Bristol-Myers Squibb Company, Clovis Oncology, GlaxoSmithKline. Dr O’Reilly — Consulting Agreements: Agios Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Berry Genomics, Celgene Corporation, Cend Therapeutics Inc, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Helio Health, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MiNA Therapeutics, QED Therapeutics, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Silenseed Ltd, SillaJen, Sobi, Surface Oncology, TheraBionic, twoXAR Inc, Vector Pharma, Yiviva; Contracted Research: Agios Pharmaceuticals Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioNTech, Bristol-Myers Squibb Company, Celgene Corporation, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Incyte Corporation, Polaris Pharmaceuticals, Puma Biotechnology Inc, QED Therapeutics, SillaJen, Yiviva. Dr Philip — Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Ipsen Biopharmaceuticals Inc, Merck, Merus BV, Novartis, Pfizer Inc, QED Therapeutics, Rafael Pharmaceuticals Inc; Consulting Agreements: Blueprint Medicines, Erytech, IQVIA, Merck, Rafael Pharmaceuticals Inc, SynCore Biotechnology, TriSalus Life Sciences; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biolinx, Bristol-Myers Squibb Company, Celgene Corporation, Corcept Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Five Prime Therapeutics Inc, Forty Seven Inc, Gritstone Oncology, Incyte Corporation, IQVIA, Karyopharm Therapeutics, Merck, Merus BV, Natera Inc, NGM Biopharmaceuticals, Novartis, Novocure Inc, QED Therapeutics, Rafael Pharmaceuticals Inc, SynCore Biotechnology, Taiho Oncology Inc, TriSalus Life Sciences, Tyme Inc; Data and Safety Monitoring Board/Committee: ASLAN Pharmaceuticals, Blueprint Medicines, Erytech; Speakers Bureau: Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Novartis.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |